Revance Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 58.13 million compared to USD 28.37 million a year ago. Net loss was USD 67.32 million compared to USD 61.44 million a year ago. Basic loss per share from continuing operations was USD 0.8 compared to USD 0.88 a year ago.
For the six months, revenue was USD 107.47 million compared to USD 53.63 million a year ago. Net loss was USD 127.11 million compared to USD 125.78 million a year ago. Basic loss per share from continuing operations was USD 1.54 compared to USD 1.82 a year ago.